The metabolically hostile tumour microenvironment imposes barriers to tumour-infiltrating
immune cells and impedes durable clinical remission following immunotherapy. Metabolic …

Cancer immunotherapy is a validated and critically important approach for treating patients
with cancer. Given the vast research and clinical investigation efforts dedicated to advancing …

Activation of the innate immune STimulator of INterferon Genes (STING) pathway potentiates
antitumour immunity, but systemic delivery of STING agonists to tumours is challenging. We …

The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted T cell
differentiation, and recent evidence suggests that their crosstalk regulates T cell exhaustion …

Obesity is a major cancer risk factor, but how differences in systemic metabolism change the
tumor microenvironment (TME) and impact anti-tumor immunity is not understood. Here, we …

Therapeutic cancer vaccines are designed to increase tumor-specific T cell immunity.
However, suppressive mechanisms within the tumor microenvironment (TME) may limit T …

KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling
protein in tumours,. The KRAS (G12C) mutant has a cysteine residue that has been …

Tracking the immune microenvironment of tumours is essential for understanding the
mechanisms behind the effectiveness of cancer immunotherapies. Molecular imaging of …

INTRODUCTION In cellular immunity, cytotoxic T lymphocytes (CTLs) and natural killer (NK)
cells use perforin to deliver serine protease granzymes into target cells to kill them …

Immune-checkpoint blockade (ICB) promotes antitumor immune responses and can result in
durable patient benefit. However, response rates in breast cancer patients remain modest …